| Development of encorafenib for BRAF-mutated advanced melanoma |
22 |
| Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? |
20 |
| Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome |
20 |
| Cutaneous angiosarcoma: update on biology and latest treatment |
15 |
| Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience |
15 |
| Molecular pathology of lung cancer: current status and perspectives |
13 |
| Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective |
13 |
| New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration |
12 |
| New insights into breast implant-associated anaplastic large cell lymphoma |
10 |
| The management of locally advanced cervical cancer |
10 |
| Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema |
10 |
| Treatment of ALK-positive nonsmall cell lung cancer: recent advances |
9 |
| Tobacco and alcohol-induced epigenetic changes in oral carcinoma |
9 |
| Current role of primary surgical treatment in patients with head and neck squamous cell carcinoma |
8 |
| Contemporary treatments in prostate cancer focal therapy |
8 |
| Treatment of cognitive deficits in brain tumour patients: current status and future directions |
8 |
| Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? |
8 |
| Reclassifying endometrial carcinomas with a combined morphological and molecular approach |
7 |
| Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer |
7 |
| Chordoma: update on disease, epidemiology, biology and medical therapies |
7 |
| Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone |
7 |
| Targeting the perivascular niche in brain tumors |
7 |
| Fertility, sexuality and cancer in young adult women |
6 |
| Photobiomodulation therapy for acute radiodermatitis |
6 |
| Immunotherapy in patients with early stage resectable nonsmall cell lung cancer |
6 |
| Novel therapeutic strategies and targets in advanced uveal melanoma |
5 |
| Adjuvant treatment for endometrial cancer |
5 |
| Mosaicism, aging and cancer |
5 |
| Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck |
5 |
| Targeting the androgen receptor and overcoming resistance in prostate cancer |
5 |
| PET imaging in renal cancer |
5 |
| The role of surgical resection in patients with brain metastases |
5 |
| Advances in prostate-specific membrane antigen PET of prostate cancer |
5 |
| Fatigue, a major still underestimated issue |
4 |
| New insights in the pathogenesis of T-cell lymphomas |
4 |
| Immunotherapy-based combinations: an update |
4 |
| Sunbeds and melanoma risk: time to close the debate |
4 |
| Targeting the interplay between metabolism and epigenetics in cancer |
4 |
| Targeting advanced urothelial carcinoma-developing strategies |
4 |
| The tumor microenvironment in renal cell cancer |
4 |
| Myelodysplastic syndromes in children |
4 |
| Adjuvant treatment of pancreatic cancer |
4 |
| Paracrine interactions of cancer-associated fibroblasts, macrophages and endothelial cells: tumor allies and foes |
4 |
| Current questions in bone sarcomas |
4 |
| Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer |
4 |
| Neurological malignancies in neurofibromatosis type 1 |
4 |
| Role of immunotherapy in stage III nonsmall cell lung cancer |
4 |
| Escalation and de-escalation in HER2 positive early breast cancer |
3 |
| Medical bioinformatics in melanoma |
3 |
| Selective oestrogen receptor degraders in breast cancer: a review and perspectives |
3 |
